EntreMed Inc. (ENMD)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
9640 Medical Center DriveRockville, MD 20850
Company Description
EntreMed is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMed's drug candidates target disease cells and the blood vessels that nourish them. The company's goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammation - processes that are vital to the progression of cancer and other diseases.
Website: http://www.entremed.com
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| MKC-1 | cell cycle inhibitor | Metastatic Breast cancer | II | |
| MKC-1 | cell cycle inhibitor | Metastatic Endometrial cancer | II | |
| MKC-1 | cell cycle inhibitor | Metastatic Ovarian cancer | II | |
| MKC-1 | cell cycle inhibitor | Non Small Cell Lung Cancer (NSCLC) | II | |
| ENMD-2076 | aurora kinase inhibitor | Platinum-resistant Ovarian cancer | II | |
| ENMD-2076 | aurora kinase inhibitor | Leukemia | I | |
| MKC-1 | cell cycle inhibitor | Leukemia | I | |
| ENMD-2076 | aurora kinase inhibitor | Multiple Myeloma | I | |
| MKC-1 | cell cycle inhibitor | Pancreatic cancer | I | |
| ENMD-1198 | antimitotic agent (oral) | Various cancer types | I | |
| ENMD-2076 | aurora kinase inhibitor | Various cancer types | I |
View additional information on product candidates here »
Recent News Headlines
[AP] - Pharmaceutical developer EntreMed Inc. said this week that its market value is too low to meet requirements to remain listed on the Nasdaq stock exchange.
[PR Newswire] - EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced that it has received a NASDAQ Staff Determination Letter indicating that the Company is currently not in compliance with the minimum Market Value of Listed Securities requirement for continued listing on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 5550, which requires the Company to have a minimum MVLS of $35 million for at least 30 consecutive business days.
[PR Newswire] - EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2010.
[PR Newswire] - EntreMed, Inc. , today announced receipt of a letter from the NASDAQ Stock Market stating that the Company has regained compliance with the $1.00 minimum closing bid price requirement and that, accordingly, it has determined to continue the listing of EntreMed's common stock on the NASDAQ Capital Market.
[PR Newswire] - EntreMed, Inc. , today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research .
(Yahoo! Finance) May 11, 2010 - EntreMed, Inc., today announced the addition of Dana Farber/Harvard Cancer Center (DF/HCC) to the Phase 2 multi-center study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Platinum Resistant Ovarian Cancer."
EntreMed, Inc. today announced that it completed a registered direct offering of 5,791,505 shares of its common stock, at a purchase price of $0.518 per share, to an existing accredited institutional investor. The sale resulted in gross proceeds to the Company of approximately $3 million. The terms of the purchase were set forth in a stock purchase agreement between the parties dated April 16, 2010.